We only use cookies that are necessary for this site to function to provide you with the best experience. The controller of this site may choose to place supplementary cookies to support additional functionality such as support analytics, and has an obligation to disclose these cookies. Learn more in our Cookie Statement.
DCP Updates: Vanguard Study Assays Selected, ULACNet Update, Upcoming Lectures, NOFOs and More
National Cancer Institute sent this bulletin at 01/14/2025 10:30 AM EST
Latest News
NCI Selects Two Assays for the Vanguard Study on Multi-Cancer Detection Tests
The National Cancer Institute has selected two assays to be included in the Vanguard Study on multi-cancer detection (MCD) tests which will be conducted by the Cancer Screening Research Network (CSRN). The two assays selected are the Avantect® Multi-Cancer Detection Test by ClearNote Health, and Shield™ Multi-Cancer Detection Test by Guardant Health.
The DCP Cancer Biomarkers Research Group presents guest lecturer, Roger Chammas, M.D., Ph.D., Professor of Oncology at the University of São Paulo, Medical School. Dr. Chammas will share research from his laboratory on the effect of signals released from dying tumor cells into the tumor microenvironment on cancer treatment and treatment failure.
Join us to kick off the 2025 season of Building Bridges in Cancer Symptom Science, where the program will focus on the complex issue of cancer cachexia. Erin Talbert, Ph.D. Assistant Professor of Health and Human Physiology at the Carver College of Medicine, University of Iowa, and Eric Roeland, M.D., Associate Professor of Medicine at the Knight Cancer Institute, Oregon Health & Science University, will share their perspectives on developing preclinical models to better understand cancer cachexia and translating this research to impactful clinical interventions.
The 2025 cohort of DCP Early Career Scientists begins their research seminar series with Mary Luz Rol, Ph.D., Scientist in the Early Detection, Prevention & Infections Branch at the International Agency for Research on Cancer, who will present, “EASTER Project Phase 1: Advancing Affordable AI-Driven Systems for Cervical Cancer Screening, Triage, and Treatment.”
Notice of Funding Opportunities (NOFOs): Cancer Risk and Prevention
Mechanisms Driving Obesity and Prostate Cancer Risk
The purpose of this Notice of Special Interest (NOSI) is to promote studies examining the mechanisms by which obesity drives aggressive prostate cancer risk. About 80% of overall prostate cancers are non-aggressive, but the biologic mechanisms driving both overall and aggressive prostate cancers are uncertain.
Cancer Prevention and Control Clinical Trials Planning Grant Program: Notice of Correction to PAR-25-104
This Notice of Correction informs applicants of a correction in the Research Plan section in PAR-25-104, Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional).
